Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.

The company reported sales of $627.7 million compared to $515.2 million a year ago, missing the consensus of $628.99 million.

Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively.

Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by strong underlying patient demand and improvement in gross-to-net dynamics.

Crenessity fourth quarter and fiscal 2024 net product sales were $2 million, reflecting initial pharmacy orders following FDA approval in December 2024

Guidance: Neurocrine Biosciences expects 2025 Ingrezza Net Product Sales of $2.5 billion-$2.6 billion.

William Blair writes that Ingrezza’s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below investor expectations.

Analyst Myles Minter writes that near-term pressures are weighing on the Ingrezza trajectory. The analyst continues to view Ingrezza as the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.

With Ingrezza still holding 14 years of potential patent protection, William Blair sees a long growth trajectory for the product, but the model addresses near-term competitive pressures ahead of the second-half 2025 salesforce expansion.

William Blair reiterates the Outperform rating on Neurocrine.

Analyst Reaction:

• BofA Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences with a Buy and lowers the price target from $184 to $179.
• Needham analyst Ami Fadia reiterates the Hold rating.
• HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and lowers the price target from $190 to $185.

Price Action: NBIX stock is down 191% at $121.98 at the last check on Friday.

Read Next:

• Spire Global Lands ~$50M Contract For Canadian Wildfire Detection; Stock Jumps